Daklinza™ (daclatasvir) – Product discontinuation

- On January 4, 2019, the FDA announced the discontinuation of Bristol Myers Squibb's Daklinza (daclatasvir) 30 mg and 60 mg tablets.
    - Previously, the FDA announced the discontinuation of Daklinza 90 mg tablets with planned distribution ceasing in December 2018.
    - Bristol Myers Squibb has planned to cease distribution for Daklinza 30 mg and 60 mg tablets in June 2019.
    - All Daklinza tablets are now discontinued.
- Daklinza is indicated for use with Sovaldi® (sofosbuvir), with or without ribavirin, for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.
    - The sustained virologic response (SVR12) rates are reduced in genotype 3 patients with cirrhosis receiving Daklinza in combination with sofosbuvir for 12 weeks.
- Daklinza carries a boxed warning for risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV.